脑心通联合瑞舒伐他汀治疗短暂性脑缺血发作临床观察

Clinical Efficacy of Naoxintong Combined with Rosuvastatin in the Treatment of Patients with Transient Cerebral Ischemia

目的分析脑心通联合瑞舒伐他汀治疗短暂性脑缺血发作(TIA)临床效果及对血脂、炎性因子的影响。方法选择2017年5月—2019年5月收治的TIA 86例,按照治疗方案分为联合组和单一组,每组43例。单一组给予瑞舒伐他汀钙片,联合组在单一组基础上给予脑心通治疗,比较2组治疗前后血脂水平、炎性因子、不良反应及临床疗效。结果治疗后2组甘油三酯、血清总胆固醇及低密度脂蛋白胆固醇低于治疗前,高密度脂蛋白胆固醇高于治疗前,且联合组改善情况优于单一组(P<0.05,P<0.01)。治疗后2组C反应蛋白、白介素-6、肿瘤坏死因子-α均低于治疗前,且联合组低于单一组(P<0.05,P<0.01)。联合组总有效率高于单一组(P<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论脑心通联合瑞舒伐他汀对TIA患者血脂水平有改善作用,同时可抑制炎性反应,疗效佳、安全性高。

Objective To analyze the clinical efficacy of Naoxintong combined with Rosuvastatin in the treatment of patients with transient cerebral ischemia and its effect on blood lipid levels and inflammatory factors.Methods A total of 86 patients with transient cerebral ischemia admitted to our hospital from May 2017 to May 2019 were selected and divided into a combination group(n=43)and a single group(n=43)according to different treatments.The single group was given Rosuvastatin calcium tablets,and the combination group was supplemented with Naoxintong.The blood lipid levels,inflammatory factors,adverse reactions and clinical effects of the two groups were compared before and after treatment.Results After treatment,the blood lipid TG,TC,and LDL-C were lower than those before treatment,while HDL-C was higher than that before treatment,and the improvement was better in combination group than in single group(P<0.05,P<0.01).And the levels of CRP,IL-6 and TNF-αwere lower than those before treatment,and the levels were lower in combination group than in single group(P<0.05,P<0.01).The total effective rate of the combination group was significantly higher than that of the single group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion Naoxintong combined with Rosuvastatin can improve blood lipid levels in the treatment of patients with transient cerebral ischemia,and can inhibit inflammatory response.It has good efficacy and safety.